Skip to main content
Springer logoLink to Springer
. 2026 Jan 28;47(2):105–115. doi: 10.1007/s00292-026-01537-y

Protein kinase-related tumors in the pediatric population

Updated review on an emerging group with emphasis on the more rarely involved kinases

Proteinkinaseassoziierte Tumoren im Kindes- und Jugendalter

Uta Flucke 1,2,, Yvonne M H Versleijen-Jonkers 3, Thomas Mentzel 4, Annette M Mueller 5, Laura S Hiemcke-Jiwa 1,6, Rita Alaggio 7,8
PMCID: PMC12945949  PMID: 41603898

Abstract

Advanced and widespread molecular techniques have deepened our understanding of mesenchymal lesions, revealing considerable overlap among morphologically defined entities now known to be related to protein kinases (PKs). This paradigm shift is important for understanding oncogenesis and also in terms of treatment options and prognosis. Therefore, it is preferable to stratify these tumors molecularly instead of morphologically, as the different categories have clinical implications. Molecular analyses are an essential and integrated part of the diagnostic workup of tissue specimens, especially those of young patients. Involved PKs range from receptor tyrosine kinases (neurotrophic tyrosine receptor kinase [NTRK]1, 2, 3; anaplastic lymphoma kinase [ALK]; proto-oncogene 1 [ROS1]; proto-oncogene [RET]; and proto-oncogene/hepatocyte growth factor receptor [MET]; etc.) to intracytoplasmic serine/threonine kinases (RAF proteins) activating the same pathways. Morphological patterns vary from infantile fibrosarcoma(-like) to lipofibromatosis(-like), dermatofibrosarcoma protuberans(-like), and malignant peripheral nerve sheath tumor-like. However, there is considerable overlap histopathologically and immunohistochemically. Most of the neoplasms are (myo)fibroblastic in type, consisting of monomorphic cells. A hemangiopericytoma-like vasculature can be a diagnostic clue. The immunophenotype is characterized by variable expression of smooth muscle actin (SMA)/desmin/CD34 or CD34/S100. This review provides updates to understand the currently known spectrum of PK-related lesions, with emphasis on those occurring more rarely, to aid proper diagnoses and treatment. The aim is to contribute to a better holistic classification.

Keywords: Soft tissue neoplasms, Immunohistochemistry, Mesenchyme, Mutation, Genetics, Protein kinases


During recent decades, advanced and widespread molecular techniques have greatly deepened our understanding of mesenchymal lesions, revealing considerable overlap among morphologically defined entities now known to be related to protein kinases (PKs).

This paradigm shift is not only important for understanding the oncogenesis of these tumors but also has a huge impact on treatment and prognosis. Therefore, attempts are made to (sub)classify tumor entities based on molecular findings, thereby opening up the possibility of therapeutically inhibiting the identified activated PK. As such, molecular analyses are an essential and integrated part of the diagnostic workup of tissue specimens, especially of those from tumors of young patients.

However, morphological suspicion/recognition seems to be the first step toward arriving at a diagnosis, as the spectrum of involved kinases is broad, and the aberrations comprise fusion genes, tandem repeat duplications, point mutations, and amplifications—all activating the kinase domain [17]. The most typical morphological growth patterns are presented in Table 1. Often, a hemangiopericytoma (staghorn)-like vasculature is present with perivascular hyalinization, which can be a diagnostic clue [5, 8].

Table 1.

Common morphological, immunohistochemical, and genetic findings of protein kinase-related mesenchymal tumors (modified from Xu et al. [8] and the 2023 World Health Organization criteria for pediatric tumors)

Tumor type Morphology, immunohistochemistry, genetics
Infantile fibrosarcoma (IFS)

More or less primitive myoid spindle cells with monomorphic oval to tapered nuclei and inconspicuous cytoplasm; arrangement in sheets and fascicles; hemangiopericytoma-like vasculature; variable expression of SMA, desmin, CD34, S100

ETV::NTRK3

IFS-like See IFS; alternative kinase fusion, e.g., NTRK1, 2, 3; ALK; LTK; RET; EGFR-KDD; BRAF; MET; FGFR1
Inflammatory myofibroblastic tumor (IMT)

More or less vague bundles of myofibroblastic cells, background loose–collagenous, SMA ±, desmin +/−, ALK +/−

ALK (~50–70%), ROS1, RET, NTRK, PDGFRB, IGF1R

IMT-like See IMT; CD34 +/−, S100 +/−
Lipofibromatosis (LPF)/LPF-like neural tumor (LPF-NT)

Irregular bundles of slender myofibroblastic cells mainly located in subcutaneous fat with a collagenous background, univacuolated small fat cells at the interface, SMA +/−, S100 +/−, CD34 +/−

NTRK1, 2, 3; EGFR; ALK; ROS; RET; LTK; FGFR1; PDGFRB

Malignant peripheral nerve sheath tumor (MPNST)-like

Often cellular, long fascicles of monomorphic spindle cells, S100 +/−, CD34 +/−

NTRK1, 2, 3; LTK; MET; RET; ALK; ROS; (B)RAF

Adult fibrosarcoma (FS)-like

Cellular, fascicular, herringbone, S100 −, CD34 +/−

For genetic changes, see MPNST-like

Myofibroma/myopericytoma

Myoid spindle cells with oval or tapered nuclei, hemangiopericytoma-like (staghorn) vasculature with hyalinization, SMA +, desmin −/+

PDGFRB

Myofibroma/myopericytoma/hemangiopericytoma-like

See myopericytoma; CD34 +/−, S100 +/−

NTRK1, 2, 3; RET

Dermatofibrosarcoma protuberans (DFSP)-like

Infiltrative storiform growth pattern, monomorphic spindle cells, CD34 +, S100 +/−

EGFR exon 20, ALK, FGFR1

Myxoid neoplasms

Variable (mostly less) cellular, vague bundles/storiform arrangement monomorphic spindle and/or epithelioid cells set in a myxoid stroma

NTRK1, 2, 3; EGFR ex 20; ALK; RET; FGFR1

Epithelioid neoplasms

Sheets/nests epithelioid/ganglion-like cells/histiocytoid, SMA +/−, desmin +/−, CD34 +/−, S100 +/−

NTRK1, 2, 3; ALK; RET

Fibrous hamartoma of infancy (FHI)

Bundles of spindle cells (between fat), nests/sheets primitive spindle to round cells, fibrous areas with giant cells (giant cell fibroblastoma-like) CD34 +/−, SMA +/−

EGFR exon 20 mutations

FHI-like

See FHI; S100 +/−, CD34 +/−

MET, FGFR1

SMA smooth muscle actin

NTRK1-/2-/3-associated tumors are the prototype and are extensively described in the literature. The first to be identified was the ETV6::NTRK3 gene fusion in infantile fibrosarcoma and congenital mesoblastic nephroma, which represented a huge step toward the new (sub)classification of such neoplasms (Fig. 1; [5, 9, 10]).

Fig. 1.

Fig. 1

a Infantile fibrosarcoma with ETV6::NTRK3, ×10 magnification. This classic example shows vague bundles and sheets of primitive myofibroblastic cells with monomorphic nuclei. b Inflammatory myofibroblastic tumor with FN1::ALK, ×10 magnification. This is a myxoid example consisting of slightly polymorphic myofibroblasts arranged loosely and in bundles, with an obviously abundant amphophilic cytoplasm. c Fibrous hamartoma of infancy-like pattern in an otherwise typical infantile fibrosarcoma with EGFR-KDD, ×5 magnification, comprising nests of primitive cells and bundles of mature slender myofibroblasts. d Lipofibromatosis pattern in an otherwise typical infantile fibrosarcoma with EGFR-KDD, ×5 magnification

Pathways that become dysregulated by ligand-independent kinase activity with autophosphorylation of tyrosine or serine/threonine are PI3K-AKT, JAK-STAT, RAS-MAPK, CRKL-C2G, and MEKK2/3-MEK5-ERK [1113].

Involved cells seem to be precursor cells, and, probably due to their developmental stage when the genetic aberration originates, they may be more or less well differentiated, which is morphologically reflected by primitive-looking or more developed neoplasms with a (myo)fibroblastic, pericytic [3, 14], or even vascular phenotype [15]. Primitive cartilage can also be present [4, 1618].

The aim of this review is to report on the variety of protein kinases involved in the oncogenesis of mesenchymal tumors, mainly of pediatric patients, with a focus on the more rarely documented PKs: EGFR, ALK, LTK, PDGFRB, MET, (B)RAF, RET, FGFR, ABL, and IGF1R. The morphological and immunohistochemical hallmarks of these tumors are presented, including their overlaps, and the usefulness of detecting them is discussed. The presented tabular algorithms aim to provide a helpful overview of this complex and emerging topic (Tables 1 and 2).

Table 2.

Altered genes encoding for protein kinases and the corresponding morphology

Involved gene Histology/tumor type
NTRK1, 2, 3 IFS(-like), IMT, LPF-like, LPF-NT, adult fibrosarcoma, MPNST-like, myopericytoma-like, epithelioid fibrous histiocytoma/superficial ALK-rearranged myxoid spindle cell neoplasm, round cell, epithelioid cell, myxoid neoplasms
EGFR exon 20 FHI, LPF, DFSP-like, myxoid spindle cell neoplasm, congenital peribronchial myofibroblastic tumor
EGFR-KDD IFS, LPF-like
EGFR rearrangement LPF/LPF-NT
EGF LPF/LPF-NT
ALK IMT, IFS, LPF-like/LPFNT, DFSP-like, 34+ plaque like dermal fibroma, spindle cell/epithelioid/myxoid neoplasms, epithelioid fibrous histiocytoma/superficial ALK-rearranged myxoid spindle cell neoplasm, hemangioma
ROS IMT, LPF-like/LPFNT, MPNST-like
LTK IFS-like, MPNST-like, LPF-like/LPF-NT
MET FHI-like, IFS-like, MPNST-like, LPF-like/LPF-NT
BRAF/RAF1 (cRAF) IFS-like, fibromatosis-like, IMT-like, MPNST-like, round cells
FGFR1 IFS-like, LPF-like/LPFNT, DFSP-like, biphasic (primitive/spindle cells), epithelioid (files), myxoid, collagenous
ABL Soft tissue angiofibroma-like, solitary fibrous tumor-like, perineurioma-like
RET IMT, IFS-like, MPNST-like, LPF-like/LPF-NT, myofibroma-like, MPNST-like, epithelioid fibrous histiocytoma/superficial ALK-rearranged myxoid spindle cell neoplasm, myxoid, epithelioid/round cell neoplasms
PDGFRB Myofibroma, myopericytoma, dermatomyofibroma, IMT, LPF
IGF1R IMT

IFS infantile fibrosarcoma, LPF lipofibromatosis, PPF-NT lipofibromatosis-like neural tumor, MPNST malignant peripheral nerve sheath tumor; FHI fibrous hamartoma of infancy, DFSP dermatofibrosarcoma protuberans, IMT inflammatory myofibroblastic tumor

EGFR-related lesions

The epidermal growth factor receptor (EGFR), a member of the ErbB family of tyrosine kinases, is altered in different mesenchymal tumors. Fusion genes, exon 20 mutations, and kinase domain duplication (KDD) activate the kinase domain and its downstream cascade to induce oncogenesis [3]. Table 3 shows the involved entities with the corresponding genetic aberrations.

Table 3.

Entities/tumor types and their corresponding EGFR alterations

Tumor type EGFR exon 20 mutations EGFR-KDD EGFR rearrangement
Fibrous hamartoma of infancy X
Lipofibromatosis X X X
Infantile fibrosarcoma X
CD34/S100+ neoplasm X
DFSP-like neoplasm X
Myxoid spindle cell neoplasm X
Mesoblastic nephroma X
Congenital peribronchial myofibroblastic tumor X

DFSP dermatofibrosarcoma protuberans, EGFR epidermal growth factor receptor, KDD kinase domain duplication

Fibrous hamartoma of infancy

Fibrous hamartoma of infancy (FHI) was first described in a series by Reye in 1954 and later on confirmed as being a separate entity with benign behavior by Enzinger in 1965, who coined the used term [19].

The lesion mainly arises in male patients with a mean age of 15 months (range birth–14 years) [1921]. Fibrous hamartoma of infancy is localized subcutaneously, commonly in the shoulder girdle. Other reported sites are the trunk, head and neck region, genital region, pelvic limb girdle, and the (lower) extremities [20, 21]. Changes of the overlying skin (discoloration, hypertrichosis, edema, tethering) are rare [20, 21]. The neoplasms usually grow slowly. Rapid growth is mainly observed in early lesions. Recurrences are identified in a few cases, commonly after incomplete excision but also after a couple of years. Long-term clinical follow-up indicates a benign clinical course [1921].

Grossly, the lesions are described as being poorly delineated, variably fibrous, and myxoid, including adipose tissue [21].

Histology shows an organoid triphasic pattern characterized by fibrocollagenous trabeculae resembling fetal tendons, desmoid fibromatosis or lipofibromatosis, and nests of primitive mesenchymal cells arranged loosely or in a whorl-like manner in a highly vascularized myxoid matrix. There is haphazardly entrapped fat, with a variable content that can exceed 50% of the tumor mass. In some cases, a variable fibrous stroma that may show slit-like pseudovascular artefacts lined by prominent stromal cells similar to giant cell fibroblastoma is observed [1921].

A few cases have been reported to show malignant transformation with cellular areas of primitive spindle and round cells with monomorphic nuclei and frequent mitotic figures [21]. Given the EGFR kinase activation in FHI and also in infantile fibrosarcoma (see below), a coincidence of different growth patterns within one tumor is not surprising.

Immunohistochemically, the neoplasms are variably positive for smooth muscle actin (SMA) and CD34, with S100 expression in the fat cells only [20, 21]. While EGFR is reported to be positive in most cases, this marker is not highly consistent and should be used with caution [3, 22].

From a genetic point of view, EGFR exon 20 insertion/duplication mutations are identified [3, 22].

Differential diagnoses are lipoblastoma, especially when fibrous or fibromyxoid areas are prominent. However, beside CD34, these cases also express desmin and the pleomorphic adenoma gene (PLAG1) due to PLAG1 rearrangement [2224]. Triphasic MET-related lesions are another differential diagnosis (see below).

Other lesions with EGFR aberrations

Other lesions with EGFR exon 20 mutations are lipofibromatosis (characterized by bundles of myofibroblastic cells with tapered nuclei traversing adipose tissue), dermatofibrosarcoma protuberance (DFSP)-like (with storiformly arranged myofibroblasts), and myxoid spindle cell neoplasm (showing a multinodular growth pattern of monomorphic spindle cells set in a myxoid matrix; Fig. 2; [3, 25]).

Fig. 2.

Fig. 2

a Spindle cell neoplasm with TPM3::NTRK1, ×10 magnification, showing vague short bundles and whorls of primitive-looking myofibroblastic spindle cells. b Spindle cell neoplasm with TMF1::RAF1, ×10 magnification In this myxoid lesion, a loose arrangement of primitive myofibroblastic spindle cells is seen. Note the entrapped collagen. c Spindle cell neoplasm with ETV6::BRAF, ×10 magnification. The primitive-looking cells are arranged in sheets possessing oval to elongated nuclei. There is a variable fibrous background, an inflammatory reaction, and deposition of hemosiderin. d Epithelioid fibrous histiocytoma with ALK rearrangement comprising epithelioid and plump spindle cells with round to oval nuclei and an amphophilic cytoplasm. Note the collagenous background

EGFR kinase domain duplication (KDD) has been found in mesoblastic nephroma, infantile fibrosarcoma, lipofibromatosis-like lesions, and congenital peribronchial myofibroblastic tumor (CPMT). All share morphological features (monomorphic primitive spindle cells arranged in more or less well-defined fascicles). However, the additional presence of primitive cartilage is typical for CPMT and may occur in mesoblastic nephroma and infantile fibrosarcoma [4, 7, 1618, 26].

EGFR fusion genes have been described in lipofibromatosis and also in the case report of a young adult with a CD34-/S100-positive tumor in his lumbar region consisting of confluent nests of slightly pleomorphic polygonal primitive cells. The nests were surrounded by a collagenous stroma [27].

In the molecularly heterogeneous group of lipofibromatosis, EGF fusions are also identified, showing that this growth pattern can be associated with the occurrence of different kinases and their ligands [28].

ALK-related lesions

The anaplastic lymphoma kinase (ALK) oncogene, located on chromosome 2p23, encodes for a cell surface receptor tyrosine kinase belonging to the insulin receptor kinase superfamily and, together with LTK, to a unique subfamily. It was first discovered as a fusion partner in anaplastic large cell lymphoma [29]. Its recurrent involvement in inflammatory myofibroblastic tumor (IMT) has been known since 1999 [30]. Whereas fusion genes are the predominant genetic aberration, it has been demonstrated that gene amplification, which also results in elevated protein expression, is an alternative mechanism in rare cases [31].

Nowadays it is known that mesenchymal lesions harboring an ALK rearrangement show a broad clinicopathologic spectrum, with affection of pediatric and adult patients and occurrence in skin, superficial and deep soft tissue, bone, viscera, and the central nervous system (CNS) [2, 3133]. However, young patients are more often involved. Beside the well-known entities, such as IMT or epithelioid fibrous histiocytoma, descriptive terms were coined to attribute to the morphology, as all neoplasms have a similar genetic background [3436]. The tumors reported to date and their features are shown in Table 4. Their morphology varies within and between tumor types, ranging from epithelioid/histiocytoid to myofibroblastic spindle cells organized in sheets, nests, bundles, and whorls in a loose, myxoid, and/or collagenous matrix with possible hyalinization. The nuclei are relatively monomorphic, either ovoid, tapered, or round with prominent nucleoli. The latter is seen in the epithelioid cells possessing also an obvious amphophilic cytoplasm. Lesions with high-grade features have enlarged nuclei, mitotic activity, and necrosis. A hemangiopericytoma-like vasculature can be prominent and therefore diagnostic [3234, 37]. Immunohistochemically, ALK expression is a perfect surrogate marker. Depending on the partner genes, subcellular localization of the ALK chimeric protein can be membranous, intracytoplasmic, or perinuclear. Other variably expressed markers are SMA, desmin, CD34, and S100 (Table 4; [13, 33]). Exceptionally, cases without ALK alteration show ALK expression [38].

Table 4.

Tumor entities/types with ALK rearrangement

Tumor type Clinical findings Histology Positive immunohistochemical results
Inflammatory myofibroblastic tumor*/inflammatory myofibroblastic sarcoma#

Children, adults*#

Intraabdominal*#, intrathoracic*#, H&N*, extremities*

(Epithelioid#) myofibroblasts, ganglion-like +/−

Bundles +/−*

Sheets#*

Collagen +/−

Myxoid −/+ inflammation

SMA, desmin, ALK (50–70% of all cases, corresponding to rearrangement)
Infantile fibrosarcoma-like

Children

Extremities, H&N, visceral

Haphazardly primitive spindle cells, bundles of myofibroblastic spindle cells, herringbone pattern +/−

Collagen +/−

Myxoid +/−

HPC-like vasculature

SMA +/−, S100 +/−, CD34 +/−
Dermatofibrosarcoma protuberans-like/CD34 + plaque-like dermal fibroma

Children, adults

Mainly skin, extremities, limb girdles, trunk, H&N

Infiltrative, storiform, vague bundles, (myo)fibroblastic spindle cells

CD34 +

S100 −

ALK +

Lipofibromatosis-like

Children, adults

Extremities, limb girdle

Sheets, nests, bundles spindle cells infiltrating fat and deeper soft tissue

Collagen +/−

Myxoid +/−

HPC-like vasculature

S100 +/−

CD34 +/−

ALK +

Spindle cell/epithelioid/myxoid neoplasms

Children, adults

Trunk, groin, paratesticular, extremities, H&N, CNS

Sheets epithelioid cells, bundles, whorls, haphazard spindle cells, enlarged or pleomorphic nuclei −/+

Collagen +/−

Myxoid +/−

HPC-like vasculature

ALK +

SMA −/+

Caldesmon −/+ H3K27me3 +/−

Epithelioid fibrous histiocytoma/superficial ALK-rearranged myxoid spindle cell neoplasm

Children, adults

Extremities, trunk, H&N

Sheets epithelioid cells +/− Round nuclei, binucleation +/−

Amphophilic cytoplasm, whorls nests, sheets, bundles histiocytoid spindle cells −/+

Collagen +/−

Myxoid +/−

(HPC-like vasculature/lipofibromatosis-like)

CD34 +/− S100 −/+ SMA −/+ EMA +/−

ALK +

Myxoid fibroblastic tumor of the vocal cord Adolescents, adults, male>>female Variable cellularity and variable myxoid background, cytological range: bland-looking spindle cells to epithelioid cells; ganglion-like with enlarged, pleomorphic nuclei, nuclear pseudoinclusions, prominent (capillary) vasculature

SMA +/−

S100 −

CD34 −

Desmin −

ALK +

Cutaneous hemangioma with epithelioid features

Children, adults

H&N, extremities, trunk

Circumscribed/nodular epithelioid endothelial cells, peripheral maturation

ERG +

CD31 +

SMA + (pericytes)

ALK +

H&N head and neck region, CNS central nervous system, HPC Hemangiopericytoma, SMA smooth muscle actin, EMA epithelial membrane antigen, ALK anaplastic lymphoma kinase, ERG avian v-ets erythroblastosis virus E26 oncogene homolog

Alternatively affected receptor tyrosine kinases are ROS, RET, and NTRK1/2/3, with NTRK3 being the prototypical gene involved in oncogenesis of infantile fibrosarcoma. This provides evidence that there is morphological overlap between protein kinase-related lesions [13, 32, 33, 37, 39].

A comprehensive review of ALK-rearranged mesenchymal tumors was recently published by Agaimy [33].

Inflammatory myofibroblastic tumor

Inflammatory myofibroblastic tumor (IMT) is the prototype of an ALK-rearranged mesenchymal tumor with myofibroblastic properties and is a member of the intermediate prognostic group (locally aggressive, rarely metastasizing) [33]. It was originally described in the lung under various terms such as inflammatory pseudotumor, plasma cell granuloma, pseudosarcomatous myofibroblastic proliferation, or inflammatory myofibrohistiocytic proliferation. It became apparent that these tumors can also occur at extrapulmonary sites, such as the mesentery and other intraabdominal/retroperitoneal locations, the small pelvis including the genitourinary tract, the head and neck region including the upper respiratory tract and the meninges, the mediastinum including the heart, the breast, and the extremities [40, 41]. The sex distribution of the patients is roughly equal, and the age range is broad, from 3 months to 46 years (mean 9 years) [40, 41]. Patients present with a mass with or without pain. Systemic symptoms are reported in 1/3 of patients, presenting with fever; weight loss; malaise; and/or peripheral blood abnormalities like anemia, thrombocytosis, elevated erythrocyte sedimentation rate, and polyclonal hypergammaglobulinemia caused by cytokine mediators [41].

The tumors can be huge. One large study reports a mean diameter of 6.0 cm (range 1–17 cm). The masses are circumscribed and firm, white or tan, showing a whorled, fleshy, or myxoid cut surface with focal hemorrhage, necrosis, and calcification in a minority of cases [40].

Histology in most IMTs is inhomogeneous and does not correlate with clinical behavior. It can be granulation tissue-like and/or tissue culture-like, resembling nodular fasciitis. Other patterns are compact spindle cell proliferation or scar tissue-like. The constituent myofibroblasts are variable in size and shape and are mainly arranged in vague fascicles. They are spindly or polygonal (ganglion-like), with round, oval, or elongated nuclei and sometimes prominent nucleoli (ganglion-like). The cytoplasm is inconspicuous or abundant and amphophilic (ganglion-like). The stroma may be loose/myxoid and/or collagenous. The inflammatory infiltrate can be more or less prominent, consisting of lymphocytes, plasma cells, eosinophils, and neutrophils [33, 40, 41].

Immunohistochemically, SMA and desmin are variably expressed, and ALK expression corresponds with the ALK genetic abnormality. It seems from the literature that up to 70% of IMTs are ALK-related [33, 41]. Other involved genes are ROS, RET, and NTRK, among other rarely involved genes (Table 1; [41]).

Differential diagnosis includes ALK-positive histiocytosis, which shows strong and diffuse CD163-positive staining. PU1.1, a nuclear marker of histiocytes, may be useful to differentiate background histiocytes from fibroblastic/myofibroblastic neoplastic cells in the case of IMT with abundant histiocytes [33].

Cutaneous hemangioma with epithelioid features and ALK rearrangement

These vascular lesions were reported recently. They are exceptional within the group of ALK-related lesions, mostly showing a myofibroblastic or, more rarely, a histiocytic phenotype. The age range of patients is 2–38 years.. Reported sites are the abdominal wall, extremities, shoulder, and head and neck region.

Histologically, lesions are circumscribed, nodular, and surrounded by an epidermal collarette. The vascular channels are lined by epithelioid endothelial cells with round, relatively monomorphous nuclei with fine chromatin and small nucleoli. The mitotic count is 4–6/10 high-power fields (HPFs). Cells have abundant eosinophilic cytoplasm showing focally intracytoplasmic vacuoles. There is maturation toward the periphery, with more distinct vessels lined by flattened endothelial cells. Pericytes are present. There is a chronic inflammatory reaction.

Immunohistochemically, lesions are positive for ERG, CD31, and ALK. Surrounding pericytes are highlighted by SMA. Other markers are negative, e.g., human herpesvirus 8 (HHV8), glucose transporter type 1 (GLUT1), and pankeratin AE. None of the control cases, including epithelioid hemangiomas and epithelioid angiomatous nodules, stained for ALK. All cases harbored an ALK fusion gene. Follow-up was uneventful.

Differential diagnoses include epithelioid angiomatous nodule and epithelioid hemangioma harboring FOS or FOSB rearrangement, with immunohistochemical expression of the corresponding proteins being negative in ALK-rearranged hemangiomas. Epithelioid hemangioendothelioma is less likely [13, 15].

ROS1

The ROS1 gene encodes for an RTK that belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The resulting type I integral membrane protein is, when altered, mainly involved in the oncogenesis of inflammatory myofibroblastic tumor (IMT; see above). A lipofibromatosis-like/lipofibromatosis-like neural tumor pattern has been reported in exceptional cases [39].

LTK-related lesions

Leucocyte receptor tyrosine kinase (LTK) is a member of the ALK/LTK family of genes. It has a homology with ALK and has been reported to be activated by a fusion transcript upregulating the kinase domain and, consecutively, the PI3K/AKT and MAPK pathways [42].

Three neoplasms were recently described with the identification of a fusion gene. Patients’ age ranged from 3 months to 17 years. Lesions originated in the muscle of the entire leg, the toe, or finger. (Long-term) follow-up was uneventful in two cases. The most extended neoplasm recurred locally.

Grossly, the tumors were described as infiltrative whitish lesions [42]. Histomorphologically, the infiltrative lesions were either composed of sheets of primitive monomorphic spindle cells or more differentiated spindle cells arranged in fascicles within a fibrous background. In two cases, a prominent hemangiopericytoma-like vasculature with perivascular fibrosis was present.

Immunohistochemically, like other PK-related lesions, CD34 and S100 were variably present, with positivity for smooth muscle markers in the more maturated myofibroblastic lesion.

At the RNA expression and methylation levels, cases were similar to DFSP and a tumor with RAF1 rearrangement, confirming that PK-related lesions are a family of tumors. However, other PK-related tumors like infantile fibrosarcoma and inflammatory myofibroblastic tumors clustered apart. Of note, such a clustering analysis depends on the included entities/cases for comparison and is therefore a matter of perspective [42, 43].

MET-related lesions

The hepatocyte growth factor receptor (HGFR) encoded by MET is a tyrosine kinase receptor. It seems to be rarely involved in the oncogenesis of PK-related mesenchymal tumors. Among the four reported tumors, patients’ age ranged from birth to 4 months. Tumors were located superficially and deep: subcutis of the lumbar area, pelvic soft tissue, thigh, trunk, and masseter muscle. The size ranged from 5.2 to 20 cm. Histologically, these tumors have a triphasic pattern like fibrous hamartoma of infancy (see above) and/or an infantile fibrosarcoma‑/MPNST-like appearance. Immunohistochemically, variable expression of S100 and CD34 has been reported. Patients have a good prognosis [39, 44, 45].

BRAF/RAF1(cRAF)-related lesions

The RAF proteins are cytosolic serine/threonine kinases activating the MAPK cascade downstream of RAS. The corresponding genes can be altered by mutations or fusion genes.

RAF1 (cRAF)

RAF1-rearranged tumors have mostly been reported in infants. Tumors were located in the arm, thigh, and kidney, with a size of up to 12 cm. The described cases were primitive looking, with variable cellularity like IFS/CMN (cellular mesoblastic nephroma), or had a more mature myofibroblastic morphology, with a fibromatosis-like appearance showing long fascicles of slender spindle cells. Nuclei were oval or tapered, monomorphous, and bland looking; S100 and CD34 were variably positive [12].

BRAF

Patients with BRAF-altered tumors ranged in age from birth to 32 years. Tumors originated in the soft tissues of the extremities, the small pelvis, and the retroperitoneum including the rectum wall and the kidney as well as in the mediastinum and the spinal, paraspinal, and head and neck regions [4, 17, 46]. When involved, skin can be ulcerated [46]. A neoplasm occurring in bone (mastoid) of a 14-year-old boy has also been described [6].

Lesions showed IFS-like and also IMT-like morphology consisting of monomorphic spindle cells, either primitive or with a more myofibroblastic phenotype possessing oval or elongated/tapered nuclei. A more or less fascicular architecture with infiltrative growth is common. Areas of round cells may be present. In the background, collagen with variable myxoid changes can be variably seen, but it is often scarce combined with high cellularity. The vascular pattern is often hemangiopericytoma-like, which can be a diagnostic clue in receptor protein kinase-related tumors mainly with an IFS-like pattern. Heterologous cartilage may occur [4, 17].

Immunohistochemically, SMA expression is seen to a variable degree, with desmin being positive in exceptional cases; CD34 and S100 positivity is observed in some cases [4, 17].

Most cases harbor a BRAF fusion gene. Alternatively, a point mutation can occur, including p.V600D, p.V600E, and p.L485F. Tandem duplications and compound deletions have also been reported. In exceptional cases, a combined BRAF fusion or a BRAF fusion gene in addition to a point mutation has been identified [4, 7, 17, 46]. Tumors may bear additional mutations, e.g., in P53 or APC [46].

In terms of follow-up, lesions may recur, also after years, but there is no apparent progression after long-term follow-up in most cases. However, aggressive behavior has been documented in isolated cases [17, 46].

Whether there is a link to metanephric stromal tumors [46] needs to be explored more thoroughly.

FGFR1-related lesions

The fibroblast growth factor receptor (FGFR) family comprises the RTKs. Normally, they become activated by binding of fibroblast growth factors. In soft tissue tumors, fusion genes are found, leading to hyperfunctioning of the kinase [14].

The reported patients were infants. Tumors were located in deep gluteal or pelvic/perirectal soft tissue, with involvement of the rectal wall. The size of the tumors ranged from 4.2 to 11 cm. Neoplasms were mainly highly cellular. They consisted of primitive spindles arranged in vague bundles, whorls, and/or sheets. Infiltration of the fat was lace-like/DFSP-like. Epithelioid cells arranged in sheets or cords were also present. Less cellular areas were collagenous or myxoid. Cellular atypia was observed after chemotherapy. Mitotic figures were scarce. Immunohistochemical analysis revealed CD34 expression without S100 staining. Patchy desmin expression was observed in rare instances. Locally aggressive behavior has been documented [47].

ABL-related lesions

The ABL family of kinase genes comprises proto-oncogenes 1 and 2 encoding for non-receptor tyrosine kinases localized in the nucleus and cytoplasm. They fuse with a variety of genes in hematological malignancies. Fusion genes in mesenchymal tumors are rare.

Lesions occurred mainly in pediatric patients (age range 7–76 years) and were localized in the trunk, limb girdles, and proximal and distal extremities, superficially or deep. Reported sizes were up to 11 cm. These tumors were misinterpreted as soft tissue angiofibroma, solitary fibrous tumors, and perineurioma.

Histologically, neoplasms are circumscribed or infiltrative and consist of bland-looking monomorphic spindle cells arranged in sheets, bundles, and whorls, with a fibrous/fibromyxoid background. When the cells have long cytoplasmic processes, they resemble perineurial cells. Mitotic activity is low.

Immunohistochemistry reveals positivity for CD34, S100, EMA, GLUT1, and claudin, with the latter three markers being characteristic of perineurioma. However, lesions mainly show morphological, immunohistochemical, and molecular features of PK-related lesions, as mentioned in Table 1.

Locally aggressive behavior seems to be an exception [48, 49].

RET-related lesions

The rearranged during transfection (RET) gene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotropic factor family of extracellular signaling molecules. The RET fusion genes are responsible for autonomic activation of the kinase, leading to oncogenesis of mesenchymal neoplasms with the typical characteristics reported for PK-related lesions.

Tumors occur in children, including newborns and infants. Adults may also be affected. Neoplasms range in size from 2.9 to 13 cm. They are located in superficial and deep soft tissue and may affect bone (chest wall). Reported sites are the proximal and distal extremities, gluteal region, trunk, neck, and visceral organs (lung, kidney).

Morphologically, neoplasms are described as IFS-like, MPNST-like, and LPF-like/LPF-NT, with sheets/bundles and whorls of monomorphic primitive spindle cells. The background is variable and can be collagenous or myxoid. A hemangiopericytoma vasculature can be prominent. In immunohistochemistry, expression of CD34, S100, and SMA was variably identifiable. Of note, ALK and ERG expression is possible.

Rarely occurring high-grade morphology with a high nuclear–cytoplasmic (NC) ratio and necrosis correlate with malignant behavior. Metastases can develop in the lung, lymph nodes, soft tissue, or CNS [38, 50].

PDGFRB-related lesions

Platelet-derived growth factor receptor beta (PDGFRB) and its paralog alpha belong to the class III family, along with c‑KIT, colony-stimulating factor 1 receptor, and FMS-like tyrosine kinase 3 receptor. They play a role in various disorders, including soft tissue tumors [51].

Pericytic tumors

Pericytic tumors comprise myofibroma, myopericytoma, angioleiomyoma, and glomus tumors. Myofibroma, myopericytoma, and angioleiomyoma are on a morphological continuum. The age range is wide, with myofibromas being very common in (early) childhood. Myofibromas occur solitarily or, less commonly, multiply (myofibromatosis) in skin/subcutis, deep soft tissue, bone, and viscera. The latter can be life threatening. Rarely, hereditary tumors are reported [52].

Morphology is typically biphasic in myofibroma, with primitive-looking areas and maturated myofibroblasts in a bluish matrix. Myopericytomas show sheets and concentric growth of primitive or maturated myofibroblasts around blood vessels and a variable collagenous background. In both tumors, an HPC-like vasculature may be obvious. The latter is also characteristic of angioleiomyomas and glomus tumors, surrounded by either leiomyocytes or glomus cells. Such lesions rarely originate in the pediatric population. Immunohistochemically, SMA and desmin are variably expressed [52, 53].

PDGFRB point mutations have been reported in all mentioned lesions. They occur in the juxtamembrane (exon 12) or kinase domain (exon 14), leading to activation of the kinase [53].

Myofibromatosis has also been shown to bear a PDGFRB fusion gene [54]. Other reported fusion genes are MTCH2-FNBP4, FN1-TIMP1, COL4A1-VEGFD (with and without PDGFRB mutation) [55].

Dermatomyofibroma

Dermatomyofibroma, first reported by Hügel in 1992, is a benign skin lesion occurring rarely in children, with neoplasms originating in the neck, shoulder girdle, trunk, and extremities. They are plaque-like and consist of fascicles of uniform slender myofibroblasts with elongated nuclei. The fascicles are parallel to the epidermis. Elastic fibers are preserved, and skin adnexal structures are spared. When infiltrating the subcutis, there are similarities with lipofibromatosis [51, 56].

Immunohistochemically, SMA, calponin, and CD34 may be positive [51, 56]. PDGFRB point mutations similar to those seen in pericytic tumors have been identified [51].

IMT, lipofibromatosis

PDGFRB fusions are more rarely documented in IMTs (see above) and also in lipofibromatosis [28, 57].

IGF1R-related lesions

Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase that binds insulin-like growth factor. The receptor is involved in physiological and pathological processes. It has an anti-apoptotic effect.

It can be an alternative fusion gene to ALK and has been reported in an inflammatory myofibroblastic tumor occurring in the duodenum of a middle-aged woman [58].

Conclusion

This review provides an update of the variety of protein kinases involved in the oncogenesis of mesenchymal tumors, mainly in pediatric patients, with a focus on the more rarely documented PKs—EGFR, ALK, LTK, PDGFRB, MET, (B)RAF, RET, FGFR, ABL, and IGF1R. The morphological and immunohistochemical hallmarks of such tumors, including their overlap, are highlighted, in order to facilitate detection of such tumors because of the therapeutic consequences.

Acknowledgments

Funding

None.

Declarations

Conflict of interest

U. Flucke, Y.M.H. Versleijen-Jonkers, T. Mentzel, A.M. Mueller, L.S. Hiemcke-Jiwa, and R. Alaggio declare that they have no competing interests.

For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

Footnotes

graphic file with name 292_2026_1537_Figqr_HTML.jpg

Scan QR code & read article online

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.van Spronsen R, Kester LA, Knops RRG et al. Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum. Ann Diagn Pathol. 2022;57:151885. [DOI] [PubMed]
  • 2.Vidrine DW, Berry JF, Garbuzov A et al. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS. Childs Nerv Syst. 2021;37(7):2147–51. [DOI] [PubMed]
  • 3.Vallese S, Barresi S, Hiemcke-Jiwa L et al. Spindle Cell Lesions with Oncogenic EGFR Kinase Domain Aberrations: Expanding the Spectrum of Protein Kinase-Related Mesenchymal Tumors. Mod Pathol. 2024;37(9):100539. [DOI] [PubMed]
  • 4.Kao YC, Fletcher CDM, Alaggio R et al. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol. 2018;42(1):28–38. [DOI] [PMC free article] [PubMed]
  • 5.Al-Ibraheemi A, Zhou Y, Rullo E, Alaggio R. What is new in fibroblastic/myofibroblastic tumors in children. Virchows Arch. 2025;486(1):127–41. [DOI] [PubMed]
  • 6.Suurmeijer AJH, Xu B, Torrence D, Dickson BC, Antonescu CR. Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature. Genes Chromosomes Cancer. 2024;63(1):e23205. [DOI] [PMC free article] [PubMed]
  • 7.Wegert J, Vokuhl C, Collord G et al. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun. 2018;9(1):2378. [DOI] [PMC free article] [PubMed]
  • 8.Xu B, Suurmeijer AJH, Agaram NP, Antonescu CR. Head and Neck Mesenchymal Tumors with Kinase Fusions: A Report of 15 Cases With Emphasis on Wide Anatomic Distribution and Diverse Histologic Appearance. Am J Surg Pathol. 2023;47(2):248–58. [DOI] [PMC free article] [PubMed]
  • 9.Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;58(22):5046–8. [PubMed]
  • 10.Rubin BP, Chen CJ, Morgan TW et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153(5):1451–8. [DOI] [PMC free article] [PubMed]
  • 11.Tognon C, Garnett M, Kenward E, Kay R, Morrison K, Sorensen PH. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res. 2001;61(24):8909–16. [PubMed]
  • 12.Motta M, Barresi S, Pizzi S et al. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors. J Pathol. 2024;263(2):166–77. [DOI] [PubMed]
  • 13.Linos K, Chang JC, Busam KJ. A cutaneous epithelioid vascular tumor harboring a TPM3::ALK fusion. Genes Chromosomes Cancer. 2024;63(1):e23207. [DOI] [PMC free article] [PubMed]
  • 14.Davis JL, Al-Ibraheemi A, Rudzinski ER, Surrey LF. Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathology. 2022;80(1):4–18. [DOI] [PubMed]
  • 15.Dehner CA, Jour G, Gassenmaier M et al. Cutaneous Hemangioma With Epithelioid Features Harboring TPM3/4::ALK Fusions : A Distinct Entity or a Molecular Variant of Epithelioid Hemangioma? Am J Surg Pathol. 2025;49(6):610–9. [DOI] [PMC free article] [PubMed]
  • 16.Younes S, Suarez CJ, Pogoriler J, Bhatti T, Shenoy A, Saab R, et al. Congenital Peribronchial Myofibroblastic Tumors Harbor a Recurrent EGFR Kinase Domain Duplication. Mod Pathol. 2025;38(2):100661. [DOI] [PubMed]
  • 17.Penning AJ, Al-Ibraheemi A, Michal M et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Mod Pathol. 2021;34(8):1530–40. [DOI] [PubMed]
  • 18.Kao E, Pinto N, Trobaugh-Lotrario A et al. Tyrosine kinase-altered spindle cell neoplasms with EGFR internal tandem duplications. Genes Chromosomes Cancer 2022;61:616–21. [DOI] [PubMed]
  • 19.Enzinger FM. Fibrous Hamartoma of Infancy. Cancer 1965;18:241–8. [DOI] [PubMed]
  • 20.Saab ST, McClain CM, Coffin CM. Fibrous hamartoma of infancy: a clinicopathologic analysis of 60 cases. Am J Surg Pathol. 2014;38:394–401. [DOI] [PubMed]
  • 21.Al-Ibraheemi A, Martinez A, Weiss SW et al. Fibrous hamartoma of infancy: a clinicopathologic study of 145 cases, including 2 with sarcomatous features. Mod Pathol. 2017;30(4):474–85. [DOI] [PubMed]
  • 22.Park JY, Cohen C, Lopez D, Ramos E, Wagenfuehr J, Rakheja D. EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy. Am J Surg Pathol. 2016;40(12):1713–8. [DOI] [PubMed]
  • 23.Fritchie K, Wang L, Yin Z et al. Lipoblastomas presenting in older children and adults: analysis of 22 cases with identification of novel PLAG1 fusion partners. Mod Pathol. 2021;34(3):584–91. [DOI] [PubMed]
  • 24.Andrei V, Zheleznyakova E, Cavalchini S et al. PLAG1-Rearranged Fibromyxoid and Lipomatous Neoplasms in Children and Adults: Separate Entities or a Morphological Spectrum? Genes Chromosomes Cancer. 2025;64(8):e70070. [DOI] [PMC free article] [PubMed]
  • 25.Fetsch JF, Miettinen M, Laskin WB, Michal M, Enzinger FM. A clinicopathologic study of 45 pediatric soft tissue tumors with an admixture of adipose tissue and fibroblastic elements, and a proposal for classification as lipofibromatosis. Am J Surg Pathol. 2000;24(11):1491–500. [DOI] [PubMed]
  • 26.Rullo E, Barresi S, Rossi S et al. EGFR-KDD Myofibroblastic Neoplasm or Congenital Peribronchial Myofibroblastic Tumor (CPMT)? Report of a Congenital Myofibroblastic Neoplasm With Unusual Histologic Features. Genes Chromosomes Cancer. 2025;64(4):e70032. [DOI] [PMC free article] [PubMed]
  • 27.Caprini E, Verkhovskaia S, Casini B et al. A spindle cell neoplasm with MYH9::EGFR fusion and co-expression of S100 and CD34, further expanding the family of kinase fusion positive spindle cell neoplasms. Genes Chromosomes Cancer. 2023;62(8):483–8. [DOI] [PubMed]
  • 28.Al-Ibraheemi A, Folpe AL, Perez-Atayde AR et al. Aberrant receptor tyrosine kinase signaling in lipofibromatosis: a clinicopathological and molecular genetic study of 20 cases. Mod Pathol. 2019;32:423–34. [DOI] [PubMed]
  • 29.Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27 Suppl 3:iii4–iii15. [DOI] [PubMed]
  • 30.Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776–80. [PubMed]
  • 31.Wang K, Guo R, Siegal GP, Wei S. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification. Pathol Res Pract. 2019;215(9):152535. [DOI] [PubMed]
  • 32.DeSimone MS, Odintsov I, Tsai HK et al. Epithelioid Fibrous Histiocytoma Is on a Continuum With Superficial ALK-rearranged Myxoid Spindle Cell Neoplasm : A Clinicopathologic Series of 35 Cases Including Alternate RET and NTRK3 Fusions. Am J Surg Pathol. 2024;48(12):1568–79. [DOI] [PubMed]
  • 33.Agaimy A. The expanding family of ALK-rearranged Mesenchymal Neoplasms. Semin Diagn Pathol 2025;42:150947. [DOI] [PubMed]
  • 34.Dermawan JK, DiNapoli SE, Mullaney KA et al. ALK-rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors. Genes Chromosomes Cancer. 2023;62(2):75–84. [DOI] [PMC free article] [PubMed]
  • 35.Dermawan JK, Azzato EM, Goldblum JR, Rubin BP, Billings SD, Ko JS. Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile. Mod Pathol. 2021;34(9):1710–8. [DOI] [PubMed]
  • 36.Agrawal S, Ameline B, Folpe AL et al. ALK-rearranged, CD34-positive spindle cell neoplasms resembling dermatofibrosarcoma protuberans: a study of seven cases. Histopathology 2024;85(4):649–59. [DOI] [PubMed]
  • 37.Tan SY, Al-Ibraheemi A, Ahrens WA et al. ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney. Histopathology. 2022;80(4):698–707. [DOI] [PubMed]
  • 38.Davis JL, Vargas SO, Rudzinski ER et al. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020;76(7):1032–41. [DOI] [PubMed]
  • 39.Kao YC, Suurmeijer AJH, Argani P et al. Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern. Genes Chromosomes Cancer. 2020;59(10):575–83. [DOI] [PMC free article] [PubMed]
  • 40.Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19(8):859–72. [DOI] [PubMed]
  • 41.Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021;45(4):100768. [DOI] [PubMed]
  • 42.Yeung MCF, Dermawan JK, Liu APY, Lam AYL, Antonescu CR, Shek TWH. Spindle cell neoplasms with novel LTK fusion—Expanding the spectrum of kinase fusion-positive soft tissue tumors. Genes Chromosomes Cancer. 2024;63(3):e23227. [DOI] [PMC free article] [PubMed]
  • 43.Furtado LV, Polanco AC, Shi Z et al. MYH9::LTK Fusion in a Pediatric Acral Soft Tissue Spindle Cell Neoplasm. Genes Chromosomes Cancer. 2024;63(10):e23277. [DOI] [PubMed]
  • 44.Flucke U, van Noesel MM, Wijnen M et al. TFG-MET fusion in an infantile spindle cell sarcoma with neural features. Genes Chromosomes Cancer. 2017;56(9):663–7. [DOI] [PMC free article] [PubMed]
  • 45.Michal M, Ud Din N, Svajdler M et al. TFG::MET-rearranged soft tissue tumor: A rare infantile neoplasm with a distinct low-grade triphasic morphology. Genes Chromosomes Cancer. 2023;62(5):290–6. [DOI] [PubMed]
  • 46.Mochel MC, Wojcik JB, Gowda M, Tye GW, Patel RM, Smith SC. Pediatric soft tissue neoplasms with BRAF activating mutations. Mod Pathol. 2022;35(7):989–92. [DOI] [PubMed]
  • 47.Warmke LM, Al-Ibraheemi A, Wang L et al. FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and “NTRK-rearranged” spindle cell neoplasms. Genes Chromosomes Cancer. 2023;62(11):641–7. [DOI] [PubMed]
  • 48.Choo F, Rakheja D, Davis LE et al. GAB1-ABL1 fusions in tumors that have histologic overlap with NTRK-rearranged spindle cell tumors. Genes Chromosomes Cancer. 2021;60(9):623–30. [DOI] [PubMed]
  • 49.Agaimy A, Perret R, Demicco EG et al. GAB1::ABL1 fusions define a distinctive soft tissue neoplasm, with variable perineurial differentiation, and a predilection for children and young adults. Genes Chromosomes Cancer. 2023;62(8):449–59. [DOI] [PubMed]
  • 50.Antonescu CR, Dickson BC, Swanson D et al. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. Am J Surg Pathol. 2019;43(10):1384–91. [DOI] [PMC free article] [PubMed]
  • 51.Flucke U, Hiemcke-Jiwa LS, van Gorp JM et al. Dermatomyofibromas harbor PDGFRB mutations—another tyrosine kinase-driven neoplasm. Virchows Arch. 2025. [DOI] [PMC free article] [PubMed]
  • 52.Jabbari S, Salari B, He M, Dehner LP. Infantile Fibrosarcoma and Other Spindle Cell Neoplasms of Infancy. A Review of Morphologically Overlapping yet Molecularly Distinctive Entities. Fetal Pediatr Pathol. 2022;41(6):996–1014. [DOI] [PubMed]
  • 53.Iwamura R, Komatsu K, Kusano M et al. PDGFRB and NOTCH3 Mutations are Detectable in a Wider Range of Pericytic Tumors, Including Myopericytomas, Angioleiomyomas, Glomus Tumors, and Their Combined Tumors. Mod Pathol. 2023;36(3):100070. [DOI] [PubMed]
  • 54.Boccia F, Barresi S, Vallese S et al. Novel PDGFRB Gene Fusions in Two Cases of Infantile Myofibromatosis. Genes Chromosomes Cancer. 2025;64(1):e70028. [DOI] [PubMed]
  • 55.Dachy G, Fraitag S, Boulouadnine B, Cordi S, Demoulin JB. Novel COL4A1-VEGFD gene fusion in myofibroma. J Cell Mol Med. 2021;25(9):4387–94. [DOI] [PMC free article] [PubMed]
  • 56.Mentzel T, Kutzner H. Dermatomyofibroma: clinicopathologic and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm. Am J Dermatopathol. 2009;31(1):44–9. [DOI] [PubMed]
  • 57.Lovly CM, Gupta A, Lipson D et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4(8):889–95. [DOI] [PMC free article] [PubMed]
  • 58.Piarulli G, Puls F, Wangberg B et al. Gene fusion involving the insulin-like growth factor 1 receptor in an ALK-negative inflammatory myofibroblastic tumour. Histopathology 2019;74:1098–102 [DOI] [PubMed]

Articles from Pathologie (Heidelberg, Germany) are provided here courtesy of Springer

RESOURCES